title: Prophylaxis of implant-related staphylococcal infections using tobramycin-containing bone cement.
abstract: In a rabbit model, premixed tobramycin-containing bone cement was studied for its efficacy to prevent infections with two frequently encountered staphylococcal species in arthroplasty surgery. After intramedullary inoculation with staphylococci, either standard or premixed tobramycin-containing Simplex-P bone cement was injected in the right femur of 120 rabbits. Development of infection was examined by culture of femoral bone after 7 or 28 days. Loss of body weight and elevated erythrocyte sedimentation rate in the control rabbits inoculated with Staphylococcus aureus were seen in the first postoperative week, returning to normal in 28 days. Inoculation with Staphylococcus epidermidis resulted only in a low-grade infection. All rabbits receiving premixed tobramycin-containing bone cement were free of signs of infection, and all their cultures were negative. Culture yield from Staphylococcus aureus controls increased with time and inoculum dose. Staphylococcus epidermidis controls needed higher inoculum doses to establish an infection, while culture yield decreased in time. These differences in mode of prosthesis-related infection are explained by differences in virulence factors.
authors.affiliation: University Cluster of Orthopaedics, University Medical Center Utrecht, G05.228, P.O. Box 85500, NL 3508 GA Utrecht, The Netherlands. nijhof@chir.azu.nl
authors.forename: M W
authors.initials: MW
authors.lastname: Nijhof
authors.forename: W J
authors.initials: WJ
authors.lastname: Dhert
authors.forename: A
authors.initials: A
authors.lastname: Fleer
authors.forename: H C
authors.initials: HC
authors.lastname: Vogely
authors.forename: A J
authors.initials: AJ
authors.lastname: Verbout
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000379:methods*; D001170:Arthritis, Infectious / Q000382:microbiology / Q000517:prevention & control*; D001843:Bone Cements / Q000737:chemistry*; D004269:DNA, Bacterial / Q000032:analysis; D004353:Drug Evaluation, Preclinical; D005260:Female; D005269:Femur / Q000382:microbiology / Q000473:pathology / Q000601:surgery; D007275:Injections, Intravenous; D008422:Materials Testing; D020366:Methylmethacrylate / Q000737:chemistry*; D023421:Models, Animal; D016133:Polymerase Chain Reaction; D016459:Prosthesis-Related Infections / Q000382:microbiology / Q000517:prevention & control*; D011817:Rabbits; D013045:Species Specificity; D013203:Staphylococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D014031:Tobramycin / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D014774:Virulence
chemical_list: D000900:Anti-Bacterial Agents; D001843:Bone Cements; D004269:DNA, Bacterial; D020366:Methylmethacrylate; D014031:Tobramycin